The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

NCT06354101 · Withdrawn

Last updated 2026-05-28

This study aims to collect health information from about 15,000 adults who are overweight or have obesity, with or without metabolic diseases, to better understand metabolic health.

Status Withdrawn Stopped before any participant enrolled.

Type Observational

Who can join Ages 18–80 · all sexes

Timeline Started 2023-07 · est. completion 2023-07

What this study is testing ClinicalTrials.gov NCT06354101 ↗

Description as written by the study sponsor.

The purpose of this registry study is to learn more about metabolic health. The information gathered will be used to support research on the natural history of obesity and weight related diseases, their treatments, and how it affects overall health. Approximately 15,000 participants who are overweight or have obesity with or without metabolic diseases are expected to participate in this registry study.

Treatments tested

Tirzepatide Drug

Once-weekly subcutaneous injectable
Semaglutide Drug

Once-weekly subcutaneous injectable

Main thing measured	Main Objective of Registry
Sponsor	CorEvitas
Conditions studied	Metabolic Health
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06354101 ↗